Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myelomaJo Caers(University of Liège), Karin Vanderkerken(Vrije Universiteit Brussel)British Journal of CancerJune 1, 200810.1038/sj.bjc.6604388Cited by 35SaveCiteExport RISWatch citationsRelated PapersMaternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease|Haematologica|2018|20